Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Core Insights - Eton Pharmaceuticals has licensed U.S. marketing rights for an ultra-rare disease product candidate, which is expected to be the first and only generic alternative for a treatment impacting fewer than 100 patients in the U.S. [1][2] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products and five additional candidates in late-stage development [3]. Product Development and Pipeline - The newly licensed product is under FDA review and is anticipated to be approved and launched in mid-2026, contributing to Eton's goal of expanding its ultra-rare disease product portfolio [2][5]. - The company aims to enhance patient and provider experiences through its Eton Cares patient support program, leveraging past successes with existing products [2].